Jennifer G. Allen

Specialty drug costs for 13 to 23 million patients in the United States would be $185 to 342 billion.

Model predicts millions of dollars can be saved just by avoiding 3 high-cost, low-reward drugs.

Are the unmeasured, potential benefits of indication-specific pricing worth the complication and risk?

Approval of first oral proteasome inhibitor, ixazomib (Ninlato), may ease treatment burden for multiple myeloma.

A new pill makes all-oral therapy possible for patients with multiple myeloma.

Policy decisions will affect how much biosimilars improve patient access to advanced treatments.

Study shows what couples with at least 1 HIV-positive partner want to get most out of HIV counseling, which can promote health services and treatment.

One clinic found little value in the early testing of infants born to HCV-infected mothers.

Finance reform is the biggest unresolved problem plaguing the US healthcare system.

Is sofosbuvir plus ribavirin a viable option for hepatitis C virus therapy after liver transplant?

Pricing and outcomes will be competitive factors in the 2 largest national drug markets into 2020.

Study finds a common assortment of reasons for non-initiation of hepatitis C therapy, regardless of patient race or ethnicity.

Disabled Medicare beneficiaries, especially those with multiple comorbidities, struggle to afford their prescriptions.

Disabled Medicare beneficiaries, especially those with many comorbidities, continue to struggle to afford prescriptions.

Special interest legislation could inflate generic drug prices.

Using PBM tools at current levels can save payers $654 billion over the next 10 years.

Nonmedical workers and mobile technology can play a pivotal role in risk prediction.

Combined with a pay-for-performance program, global budgets put provider organizations at risk of incurring medical expenses above a predetermined amount.

Study finds patient health literacy inversely associated with healthcare utilization and costs, especially for prescriptions.

Study examines how pharmaceutical companies use social media to market products and interact with the public.

Illegal ads and unmoderated drug reviews potentially mislead social media users.

Study estimates the private sector could save much more than the public sector would spend.

A new decision-making tool aims to make effective treatments available to more patients within a set budget.

A pilot demonstration will measure the extent of probable fraud in the home health industry

An anti-fraud pilot demonstration is planned for home health agencies in several states.

Differential pricing influences drug use, but more research is needed to assess its value and health outcomes.

Tighter restrictions led to discontinuation, adherence, generic use, and cost reduction.

Study finds dispensing behavior to be largely compliant with payers, especially in competitive regions.

Combination therapy with lenalidomide and dexamethasone plus bortezomib in multiple myeloma patients shows significant improvement.

A study found positive outcomes of dose-attenuated combination therapy with lenalidomide and dexamethasone plus bortezomib in multiple myeloma patients.